News
Zacks Investment Research on MSN2h
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...
For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...
CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback